Skip to main content

Table 1 Concentration of l-DOPA, dopamine and their metabolites in striatal astrocytes 4 h after methyl-l-DOPA (100 µM) and/or 3-OMD (10 µM) exposure

From: 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of l-DOPA

  Control 3-OMD Methyl-l-DOPA 3-OMD + methyl-l-DOPA
l-DOPA N.D. N.D. 411.0 ± 12.1** 347.0 ± 15.6**, ##
DA N.D. N.D. N.D. N.D.
DOPAC N.D. N.D. N.D. N.D.
HVA N.D. N.D. N.D. N.D.
3-OMD N.D. 12.5 ± 1.02** 15.3 ± 1.57** 26.0 ± 0.83**, ## , $$
  1. Striatal astrocytes were treated with methyl-l-DOPA (100 µM) and/or 3-OMD (10 µM) for 4 h. The concentrations of l-DOPA, DA, DOPAC, HVA and 3-OMD were measured by HPLC assay. N.D: not detected. Data (pmol/mg protein) are presented as mean ± SEM (n = 4)
  2. * p < 0.05, ** p < 0.001 versus control group
  3. ## p < 0.001 versus methyl-l-DOPA-treated group
  4. $$p < 0.001 versus 3-OMD-treated group